$ERAS

Erasca (NasdaqGS:ERAS) reported wider Q2 and first-half 2026 net losses, filed a US$112.34 million ESOP-related shelf registration, disclosed a US securities class action tied to its ERAS-0015 program, and appointed Charles S. Fuchs as president of R&D. The piece discusses how these items affect the ERAS-0015 investment narrative and cites fair value estimates from US$4.96 to US$23.30.

Erasca raised about $891.3M gross across two 2026 public offerings, including $632.5M in an upsized July offering and $258.8M in an upsized January offering. Cash was $384.3M as of June 30. The company says proceeds will fund accelerated development of ERAS-0015 and three potentially registration-enabling studies starting 2027-2028.

Analyst estimates for Erasca, Inc. show the average 12-month price target increased from $22.55 to $22.73, with a range of $18 to $30, according to 11 analysts. Based on the Aug. 11 close, the target suggests about 24% upside. The consensus rating remains “Buy” with 9 Buys, 2 Holds, and 0 Sells.

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Erasca Reports Second Quarter 2026 Business Updates and Financial Results Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as

Simply Wall St reports Erasca (ERAS) appointed Charles S. Fuchs as president of R&D, citing his oncology and biopharma background. The article notes ERAS shares fell 1.6% over one day and 2.2% over a month, while showing strong YTD and 1-year returns. It highlights a 16x price-to-book versus industry 2.5x and peers 11.9x, with zero revenue and a $277.02M net loss.

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001761918 0001761918 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10

Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).

Levi & Korsinsky said investors who bought Erasca, Inc. (NASDAQ: ERAS) shares between Jan. 14, 2025 and Apr. 26, 2026 may seek damages in a pending class action. The firm links ERAS’s ~53.9% drop and about $11.59 per share loss to April 27, 2026 disclosures about alleged patent infringement, a Grade 5 patient death, and limits of prior cross-study comparisons. Lead plaintiff deadline is Aug. 10, 2026.

Erasca, Inc. (Nasdaq: ERAS) said it closed an upsized public offering of 36,142,857 shares of common stock at $17.50 per share, including 4,714,285 shares from the underwriters’ option. Gross proceeds were about $632.5 million. Erasca plans to use net proceeds for R&D, working capital, and general corporate purposes.

Erasca Inc. (NASDAQ:ERAS) shares rose 8.94% to $19.50 after phase 1 data for ERAS-0015 in RAS-mutant solid tumors. In pancreatic cancer, tumors shrank 57% after eight weeks in 7 patients. Jefferies raised its price target 14% to $24 and reiterated a buy. Erasca launched a follow-on offering to raise up to about $632M.